Antibody Drug Conjugates Keep Growing: What to Know

Desde 2018, se ha producido un crecimiento exponencial de más de 60.000 millones de dólares en acuerdos de licencia relacionados con conjugados de fármacos anticuerpos (ADC), y en 2023 habrá al menos 18 acuerdos. Se prevé que los ADC en todo el mundo alcancen los 20.000-30.000 millones de dólares anuales en un futuro próximo.

Foley’s Health Care & Life Sciences and Innovative Technology sectors invite you to join us for a webinar on how your organization can navigate the crossroads of ADCs and how you can prepare for this evolving landscape.

This webinar will explore the following:

•    An inside look on the U.S. Food & Drug Administration’s (FDA) perspective on ADCs.
•    How to prepare and secure your patents and safeguard your ADC intellectual property.
•    The do’s and don’ts of an ADC merger and acquisition.
•    Litigation trends in the ADC industry.
•    Clinical trial considerations for ADCs.

To watch the recording of this webinar, please click here.